Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Segment Reporting Information
Net sales		$ 793.9	$ 887.2	$ 2,429.3	$ 2,569.6
Operating Segments
Segment Reporting Information
Net sales		780.5	872.9	2,386.8	2,525.0
Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		591.4	633.1	1,743.1	1,757.4
Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		189.1	239.8	643.7	767.6
Corporate, Non-Segment
Segment Reporting Information
Net sales	[1]	13.4	14.3	42.5	44.6
Acthar | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		308.7	327.0	899.9	873.7
Inomax | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		125.7	126.9	379.6	363.5
Ofirmev | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		75.4	75.6	224.5	217.4
Therakos immunotherapy | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		55.3	54.5	157.7	157.2
Hemostasis Products | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		16.2	17.2	42.8	42.5
Other | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		10.1	31.9	38.6	103.1
Other | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		47.5	45.0	142.6	129.8
Hydrocodone (API) and hydrocodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		10.0	30.8	63.3	109.8
Oxycodone (API) and oxycodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		13.4	28.8	60.6	97.3
Methylphenidate ER | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		14.3	23.4	58.2	72.3
Other Controlled Substances | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		$ 103.9	$ 111.8	$ 319.0	$ 358.4

[1] Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.